Insights into Austria’s Pricing and Pharmaceutical Policy

By Danélia Botes

April 30, 2024


Healthcare systems worldwide are under pressure to balance quality care with cost containment. The Austrian pharmaceutical policy serves as a compelling case study. The Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Brief provides a window into the Austria’s approach to pharmaceutical policy and reimbursement, offering valuable insights for stakeholders in the pharmaceutical and health economics of the continent.

Understanding the Austrian Pharmaceutical Policy

Austria’s healthcare system distinguishes sharply between outpatient and inpatient services, each governed by distinct policies and authorities. The Federal Ministry of Social Affairs, Health, Care and Consumer Protection sets the legislative tone, while the Austrian Social Insurance plays a pivotal role in outpatient reimbursement decisions.

Pharmaceutical Expenditure in Focus

With a pharmaceutical expenditure (PE) of €627.1 per capita, representing 11.4% of the health expenditure (HE), Austria demonstrates a significant investment in medications. The public PE accounts for 67.5% of the total PE, underlining the government’s commitment to subsidising medicine costs for its population.

Pharmaceutical Provision and Market Dynamics

With 1,415 community pharmacies and 884 dispensing doctors, Austria provides extensive access to medications. Additionally, the pharmaceutical market holds a significant value of €5.7 billion. This robust sector authorises 15,976 medicines, out of which 7,517 are on the outpatient reimbursement list.

Pricing Policies and Reimbursement Mechanisms

Austria employs a range of pricing policies, from external price referencing for outpatient medicines to free pricing for hospital-used drugs. Notably, managed-entry agreements are increasingly utilised for high-priced medicines, reflecting a shift towards more sophisticated pricing strategies.

The Role of Generics and Biosimilars

Generic market shares stand at 37% in volume and 13% in value, indicating room for growth in this segment. Austria’s ‘price link policy’ for generics and biosimilars aims to encourage their uptake by aligning their prices with those of originator medicines.

The Outpatient Reimbursement List: A Strategic Tool

The outpatient Code of Reimbursement (EKO) is a national positive list that classifies medicines into specific categories, each with its prescribing rules. This strategic tool ensures that the reimbursement process aligns with pharmacological, medical-therapeutic, and health-economic evaluations.

Co-payments and Patient Impact

The reimbursement list includes outpatient medicines, covering 100% of their cost. Patients only need to pay a prescription fee of €6.85, except when they are exempted. By doing so, out-of-pocket expenses are significantly reduced. Consequently, essential drugs become more accessible to the public in Austria.


Austria’s pharmaceutical policy reflects a sophisticated balance between ensuring access to medications and managing expenditure. As life sciences consulting firms and value-based healthcare companies observe, the nation’s strategies provide a blueprint for sustainable pharmaceutical pricing and reimbursement models.

Reference url

Recent Posts

Epidemic intelligence

How User-Centered Perspectives Foster Innovation in Digital Health Surveillance for Epidemic Intelligence in Europe

🌍🔬European Epidemic Intelligence: Overcoming Challenges in Data Reporting and Surveillance 📊🦠

Effective epidemic intelligence is crucial for managing public health threats. Discover the challenges faced by practitioners and the proposed improvements to enhance data reporting and surveillance systems. Let’s work together to build a healthier future! 💪

#EpidemicIntelligence #PublicHealth #DataReporting #Surveillance #HealthcareInnovation #AIConsulting #LifeSciences #ValueBasedHealthcare #MarketAccess

Join the conversation and share your thoughts on improving epidemic intelligence! 💬

Quality-Adjusted Life Year (QALY)

Quality-Adjusted Life Year (QALY) in Modern Healthcare Decision-Making

🔍 Understanding QALYs in Healthcare Decision-Making 🔍

The recent passage of HR 485 has sparked a debate on the use of Quality-Adjusted Life Years (QALYs) in healthcare. QALYs are crucial for measuring the effectiveness of medical treatments, ensuring fair treatment for all. Learn about their importance and the potential implications of HR 485.

#Healthcare #MedicalResearch #QALYs #HealthPolicy #HealthEconomics #MedicalInnovation


Patient Empowerment in Their Pockets: AI Chatbots in Healthcare

🧠 Unlocking the Power of AI: Chatbots Simplifying Pathology Reports 📊 Explore how artificial intelligence is transforming patient understanding of complex medical data. Learn more about the potential impact on healthcare communication and accessibility. #HealthTech #PatientCare #AIInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.